This website is intended for use by residents of Sweden only

About Isofol

Isofol Medical AB (publ) aims to raise the quality of life and increase the survival rate for patients with severe forms of cancer. The company’s drug candidate arfolitixorin is being developed with the purpose of increasing the efficacy of standard first-line treatment for several forms of solid tumours, including colorectal cancer. The next step in the clinical development program is currently being prepared based on a new dosage regimen that is expected to optimize arfolitixorin’s efficacy.

Isofol Medical AB (publ) is traded on Nasdaq Stockholm.


Upcoming Events

  • August 21, 2024 - August 21, 2024
    Interim report January-June 2024
  • November 12, 2024 - November 12, 2024
    Interim report June-September 2024


Stay updated on the latest news by
following Isofol on Linkedin.

LinkedIn logotype
Scroll to Top